Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma.
- DOI
- 10.1016/j.jhep.2026.01.006
- Published
- 2026 Jun
- Container
- Journal of hepatology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.jhep.2026.01.006,
title = {Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma.},
author = {Yopp A and Chen M and Cheng AL and Kaseb A and Kudo M and Lee HC and Cha E and Hack SP and Lian Q and Spahn J and Wu C and Qin S and Chow PK},
year = {2026},
journal = {Journal of hepatology},
doi = {10.1016/j.jhep.2026.01.006},
url = {https://doi.org/10.1016/j.jhep.2026.01.006}
}RIS
TY - JOUR TI - Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma. AU - Yopp A AU - Chen M AU - Cheng AL AU - Kaseb A AU - Kudo M AU - Lee HC AU - Cha E AU - Hack SP AU - Lian Q AU - Spahn J AU - Wu C AU - Qin S AU - Chow PK PY - 2026 JO - Journal of hepatology DO - 10.1016/j.jhep.2026.01.006 UR - https://doi.org/10.1016/j.jhep.2026.01.006 ER -
APA
A, Y., M, C., AL, C., A, K., M, K., HC, L., E, C., SP, H., Q, L., J, S., C, W., S, Q., & PK, C. (2026). Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma.. Journal of hepatology. https://doi.org/10.1016/j.jhep.2026.01.006
Source records
- pubmed · retrieved 2026-09-27T12:46:59.752Z